Generic Name and Formulations:
Aztreonam 75mg/vial; pwd for inhalation via nebulization after reconstitution; preservative-free.

Company:
Gilead Sciences, Inc.
Indications for CAYSTON:
To improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.

Adults and Children:
<7yrs: not established. Use a short-acting bronchodilator 15 minutes to 4 hours before each dose; or a long-acting bronchodilator 30 minutes to 12 hours before starting therapy. >7yrs: 75mg (1 vial) by nebulization three times daily (at least 4 hours apart) for 28 days. Use Altera Nebulizer only.

Warnings/Precautions:
Monobactam or beta-lactam allergy. FEV<25% or >75% predicted, patients colonized with Burkholderia cepacia: safety/effectiveness not established. Pregnancy (Cat.B).

Interactions:
Do not mix with other drugs in nebulizer.

Pharmacological Class:
Monobactam.

Adverse Reactions:
Cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, vomiting, rash; chest tightness, bronchospasm, allergic reactions (discontinue if occurs).

Note:
To support and assist patients with cystic fibrosis contact the Cayston Access Program at (877) 7CAYSTON. Should be administered immediately after reconstitution. Do not reconstitute until ready to administer a dose.

Generic Availability:
NO

How Supplied:
Vials—84 (w. diluent)